Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610559917/en/
Contacts
Investor Contact: Andrew McKibbenir@mirumpharma.com
Media Contact: Erin Murphymedia@mirumpharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Westwater Resources Announces Second Quarter 2025 Business Update Call
CENTENNIAL, Colo.--(BUSINESS WIRE)-- Westwater Resources, Inc. (NYSE American: WWR), an energy technology and battery-grade natural graphite company ('Westwater' or the 'Company'), will host a conference call and webcast on August 14, 2025, at 11:00 AM Eastern Daylight Time to discuss its second quarter 2025 results, recent operational developments, and key strategic priorities. A replay of the webcast will be available on Westwater's website following the event. Conference Call and Webcast Details Time and Date: 11:00 AM EDT Webcast Link: Dial-Ins: Canada / USA Toll Free: 1-833-752-3988 International Dial-In: 1-647-849-3183 About Westwater Resources, Inc. Westwater Resources is an energy technology company that is focused on developing battery-grade natural graphite. Westwater Resources' primary project is the Kellyton Graphite Processing Plant that is under construction in east-central Alabama. In addition, Westwater Resources' Coosa Graphite Deposit is the largest and most advanced natural flake graphite deposit in the contiguous United States — and is located across 41,965 acres (~17,000 hectares) in Coosa County, Alabama. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words and phrases such as 'priorities,' and other similar words. Forward looking statements include, among other things, statements concerning: operational developments including the construction of the Kellyton Graphite Plant, the Coosa graphite deposit, and the costs, schedules, production and economic projections associated with both of them, and strategic priorities including progress on the syndication of the secured debt financing for the Kellyton Graphite Plant. The Company cautions that there are factors that could cause actual results to differ materially from the forward-looking information that has been provided. The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of the Company; accordingly, there can be no assurance that such suggested results will be realized. Those uncertainties and other factors are discussed in Westwater's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent securities filings, and they could cause actual results to differ materially from management expectations.
Business Wire
an hour ago
- Business Wire
Venture Global, Inc. Announces Updated Timing for Release of Second Quarter 2025 Earnings
ARLINGTON, Va.--(BUSINESS WIRE)--Venture Global, Inc. ('Venture Global') (NYSE: VG) announced that it plans to release its second quarter 2025 financial results before market open on Tuesday, August 12, 2025. As previously announced, Venture Global will host a conference call for investors and analysts beginning at 9:00 am Eastern Time (ET) on Wednesday, August 13, 2025, to discuss second quarter results. A listen-only webcast of the conference call and accompanying slide presentation will be available at Venture Global's Investor Relations website HERE. After the conclusion of the conference call, a replay will be made available on the Venture Global website. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company's vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company's first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.
Business Wire
an hour ago
- Business Wire
Community Health Systems, Inc. Announces Consideration for Tender Offer for Its 5.625% Senior Secured Notes Due 2027
FRANKLIN, Tenn.--(BUSINESS WIRE)--Community Health Systems, Inc. (the 'Company') (NYSE: CYH) announced today the consideration payable in respect of the previously announced cash tender offer (the 'Tender Offer') by its wholly owned subsidiary, CHS/Community Health Systems, Inc. (the 'Issuer'), to purchase any and all of the Issuer's outstanding 5.625% Senior Secured Notes due 2027 (the '2027 Notes'), on the terms and subject to the conditions set forth in the Offer to Purchase, dated July 28, 2025, as amended (the 'Offer to Purchase'). The consideration (the 'Early Tender Consideration') of $1,002.65 per $1,000 principal amount of 2027 Notes that were validly tendered at or prior to the Early Tender Deadline (as defined below) and are accepted for purchase pursuant to the Tender Offer was determined in the manner described in the Offer to Purchase by reference to the fixed spread specified in the table below plus the yield of 4.293%, which is based on the bid-side price of the U.S. Treasury security specified in the table below, as quoted on the Bloomberg Reference Page specified in the Offer to Purchase, calculated as of 10:00 a.m., New York City time, on August 11, 2025, and includes an early tender premium of $30 per $1,000 principal amount of 2027 Notes (the 'Early Tender Payment'). Only holders of 2027 Notes who validly tendered their 2027 Notes at or prior to the Early Tender Deadline, and whose 2027 Notes have been accepted for purchase, will receive the Early Tender Consideration (which includes the Early Tender Payment). Holders of 2027 Notes tendered following the Early Tender Deadline, but on or prior to the Expiration Time (as defined below) and accepted for purchase will receive an amount equal to the Early Tender Consideration minus the Early Tender Payment (the 'Late Tender Consideration'). The settlement date for 2027 Notes validly tendered as of the Early Tender Deadline and accepted for purchase is expected to occur on August 12, 2025. In addition to the Early Tender Consideration or the Late Tender Consideration, as applicable, holders whose 2027 Notes are purchased in the Tender Offer will receive accrued and unpaid interest on such 2027 Notes from and including the last interest payment date for the 2027 Notes up to, but not including, the applicable settlement date for such 2027 Notes accepted for purchase. The Tender Offer is scheduled to expire at 5:00 p.m., New York City time, on August 25, 2025 (the 'Expiration Time'), unless extended or earlier terminated by the Issuer. The Tender Offer is subject to the satisfaction or waiver of certain conditions as described in the Offer to Purchase. The complete terms and conditions of the Tender Offer are set forth in the Offer to Purchase and remain unchanged. The Issuer has retained Citigroup Global Markets Inc. to act as dealer manager in connection with the Tender Offer. Questions about the Tender Offer may be directed to Citigroup Global Markets Inc. at (800) 558-3745 (toll free) or (212) 723-6106 (collect). Copies of the Tender Offer documents and other related documents may be obtained from Global Bondholder Services Corporation, the depositary and information agent for the Tender Offer, at (855) 654-2015 (toll free) or (212) 430-3774 (collect), or by email at contact@ This press release shall not constitute an offer to buy or sell, or the solicitation of any offer to buy or sell, any securities. Any offer or solicitation with respect to the Tender Offer will be made only by means of the Offer to Purchase, and the information in this press release is qualified by reference to the Offer to Purchase. The Tender Offer is not being made to holders of 2027 Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In addition, nothing contained herein constitutes a notice of redemption of the 2027 Notes. Holders must make their own decision as to whether to tender any of their 2027 Notes, and, if so, the principal amount of 2027 Notes to tender. Forward-Looking Statements This press release may include information that could constitute forward-looking statements. These statements involve risk and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.
